AMLX vs BIIB · $561.6M cap vs P/E 21, rev $9.89B
Amylyx Pharmaceuticals Inc (AMLX) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
AMLX currently screens at market cap $561.6M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the AMLX and BIIB stock pages for the full models.
Not investment advice.